Invokana (canagliflozin) lawsuits have been popping up around the country. According to the claims brought against Janssen Pharmaceuticals and parent company Johnson & Johnson, these companies failed to warn of the possible serious side effects associated with Invokana use.
According to one complaint filed in the Eastern District of California, a plaintiff was proscribed Invokana to treat her type 2 diabetes and she took as directed. Sometime after taking it, she was hospitalized for diabetic ketoacidosis (DKA) – a condition where the blood becomes too acidic, and can lead to serious health complications, including death.
After learning of at least 20 reports of patients with type 2 diabetes who were hospitalized for DKA after taking the drug, this past May the FDA warned doctors and patients about a possible link between Invokana and DKA. According to the FDA, DKA is a “type of acidosis that usually develops when insulin levels are too low or during prolonged fasting,” which is why DKA is most common in patients with type 1 diabetes, and is usually accompanied by high sugar levels. The FDA noted that the reports they received of patients with type 2 diabetes suffering from DKA “were not typical” because their blood sugar levels were only slightly increased compared to the greater increases normally seen in typical cases of DKA.